Synektik (SNTP) Q4 2024 earnings summary

Executive summary

• Revenue increased by 40% year-over-year to PLN 624.8 million for the period ending September 30, 2024, with net profit up 61% to PLN 84.6 million.

• Strong growth in both medical equipment and radio-pharmaceuticals segments, with recurring revenues and international expansion driving results.

• EBITDA rose 50% year-over-year to PLN 146.3 million, with margin improvement to 23.4%.

• No significant legal, financial, or operational disruptions reported during the period.

Financial highlights

• Revenue: PLN 624.8 million (up 40% year-over-year).

• Net profit: PLN 84.6 million (up 61% year-over-year).

• EBITDA: PLN 146.3 million (up 50% year-over-year).

• Operating cash flow: PLN 88.1 million; net cash increased by PLN 21.7 million.

• EPS: PLN 9.92 (up from PLN 6.15 year-over-year).

Outlook and guidance

• Management expects continued growth in medical equipment, IT, and service revenues, supported by new product launches and geographic expansion.

• Expansion into the Baltic states and new exclusive distribution agreements are expected to drive future results.

• No formal financial guidance was issued for the next period.